ORKA vs. OCUL, CALT, EVO, AMPH, ADPT, IOVA, ARDX, GPCR, AUPH, and SNDX
Should you be buying Oruka Therapeutics stock or one of its competitors? The main competitors of Oruka Therapeutics include Ocular Therapeutix (OCUL), Calliditas Therapeutics AB (publ) (CALT), Evotec (EVO), Amphastar Pharmaceuticals (AMPH), Adaptive Biotechnologies (ADPT), Iovance Biotherapeutics (IOVA), Ardelyx (ARDX), Structure Therapeutics (GPCR), Aurinia Pharmaceuticals (AUPH), and Syndax Pharmaceuticals (SNDX). These companies are all part of the "pharmaceutical products" industry.
Oruka Therapeutics vs.
Ocular Therapeutix (NASDAQ:OCUL) and Oruka Therapeutics (NASDAQ:ORKA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, community ranking, analyst recommendations, institutional ownership, media sentiment and dividends.
59.2% of Ocular Therapeutix shares are owned by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are owned by institutional investors. 3.5% of Ocular Therapeutix shares are owned by company insiders. Comparatively, 22.7% of Oruka Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Ocular Therapeutix has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500. Comparatively, Oruka Therapeutics has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500.
In the previous week, Ocular Therapeutix had 2 more articles in the media than Oruka Therapeutics. MarketBeat recorded 7 mentions for Ocular Therapeutix and 5 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 0.99 beat Ocular Therapeutix's score of 0.80 indicating that Oruka Therapeutics is being referred to more favorably in the news media.
Ocular Therapeutix presently has a consensus target price of $16.38, suggesting a potential upside of 124.01%. Oruka Therapeutics has a consensus target price of $39.86, suggesting a potential upside of 332.52%. Given Oruka Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Oruka Therapeutics is more favorable than Ocular Therapeutix.
Oruka Therapeutics has lower revenue, but higher earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Oruka Therapeutics, indicating that it is currently the more affordable of the two stocks.
Oruka Therapeutics has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -283.74%. Oruka Therapeutics' return on equity of -24.96% beat Ocular Therapeutix's return on equity.
Ocular Therapeutix received 425 more outperform votes than Oruka Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Oruka Therapeutics an outperform vote while only 70.27% of users gave Ocular Therapeutix an outperform vote.
Summary
Oruka Therapeutics beats Ocular Therapeutix on 11 of the 18 factors compared between the two stocks.
Get Oruka Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ORKA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oruka Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ORKA) was last updated on 4/18/2025 by MarketBeat.com Staff
Buy ORKA Stock Free ORKA Stock Alerts